Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Marco L. Davila, MD PhD, Eunice S. Wang, MD, Doreen Dekker, PhD, Sarah Snykers, PhD, Panagiota A. Sotiropoulou, PhD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Jason B. Brayer, PhDMD

Blood (2018) 132 (Supplement 1): 902.

https://doi.org/10.1182/blood-2018-99-111326

Published: 2018

Journal Articles

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Timothy Devos, Koen Theunissen, Fleur Samantha Benghiat, Alain Gadisseur, Stef Meers, Dominik Selleslag, Gaëtan Vanstraelen, Pierre Zachée, Marc André, Philippe Lewalle, MD, Mia Janssen, Rik Schots, Koen Van Eygen, Alain Kentos, Marie Lejeune, Agnes Triffet, Inge Vrelust, Carolina Kuipers, Violaine Havelange

Blood (2018) 132 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2018-99-114070

Published: 2018

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

Journal Articles

Long-Term Overall and Event-Free Survival after RIC Allogeneic Transplantation in Acute Leukemias in a Single Centre - Impact of Age and Donor Type?

Sebastian Wittnebel, MD PhD, Philippe Lewalle, MD PhD, Sandra Michiels, Soumaya Anoun, MD, Benjamin Bailly, MD, Marie Vercruyssen, MD, Julie Dallemagne, MD, Sarah Buntinx, MD, Phuong Huynh, MD, Patrick Crombez, Marie France Jaivenois, Dominique Bron, MD PhD

Blood (2015) 126 (23): 5454.

https://doi.org/10.1182/blood.V126.23.5454.5454

Published: 2015

Journal Articles

Identification of the Microrna Signature of Acute Myeloid Leukemia Patient s Regulatory T Lymphocytes

Redouane Rouas, PhD, Makram Merimi, PhD, Bassam Badram, PhD, Arsene Burny, MD PhD, Dominique Bron, Philippe Lewalle, MD PhD, Hussein Fayyad Kazan, PhD

Blood (2015) 126 (23): 4967.

https://doi.org/10.1182/blood.V126.23.4967.4967

Published: 2015

Journal Articles

Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS

Denis-Claude Roy, MD, Johan Maertens, MD PhD, Irwin Walker, MBBS, Silvy Lachance, MD, Jean Roy, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Dominik L.D. Selleslag, MD, Liesbeth De Jong, PhD, Jurjen H.L. Velthuis, PhD, Lisya Gerez, PhD, Karen Reitsma, PhD, Edwin Wagena, PhD, Stephan Mielke, MD

Blood (2014) 124 (21): 314.

https://doi.org/10.1182/blood.V124.21.314.314

Published: 2014

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society

Yves Beguin, MD PhD, Pierre Zachee, MD PhD, Johan Maertens, MD PhD, Tessa Kerre, MD PhD, Aurelie Ory, Laurence Seidel, Carlos Graux, MD PhD, Philippe Lewalle, MD PhD, Michel Van Gelder, PhD MD, Koen Theunissen, Evelyne Willems, MD PhD, Marie-Paule Emonds, Ann De Becker, Frederic Baron

Blood (2014) 124 (21): 542.

https://doi.org/10.1182/blood.V124.21.542.542

Published: 2014

Journal Articles

Preemptive Management of Epstein-Barr Virus Reactivation after Hematopoietic Stem Cell Transplantation.

Imran Ahmad, MD, John Kwan, MD, Nathalie Meuleman, MD, Philippe Lewalle, MD, Francoise Crokaert, MD, PhD, Dominique Bron, MD, PhD

Blood (2007) 110 (11): 5000.

https://doi.org/10.1182/blood.V110.11.5000.5000

Published: 2007

Journal Articles

Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation (HSCT) with Mesenchymal Stem Cells (MSC) Infusion for Treatment of Metachromatic Leukodystrophy (MLD): A Case Report.

Nathalie Meuleman, MD, C. Rocha, MD, Jalil Bennani, MD, Tatiana Tondreau, PhD, Alain Delforge, MD, Philippe Lewalle, MD, Philippe Martiat, PhD, Laurence Lagneaux, PhD, Dominique Bron, PhD

Blood (2006) 108 (11): 5255.

https://doi.org/10.1182/blood.V108.11.5255.5255

Published: 2006

Journal Articles

The Role of GM-CSF in Haplo-Identical Transplant Patients Who Do Not Benefit from NK Alloreactivity.

Philippe Lewalle, MD, Alain Delforge, PhD, Berengere Nowak, BSc, Virginie Misplon, BSc, Jalil Bennani, MD, PhD, Dominique Bron, MD, PhD, Philippe Martiat, MD, PhD

Blood (2005) 106 (11): 2912.

https://doi.org/10.1182/blood.V106.11.2912.2912

Published: 2005

Journal Articles

Can Addition of GM-CSF in Adult Haplo-Identical Transplant Who Cannot Benefit from NK Alloreactivity Improve the Relapse Rate of Advanced Leukemia: A 3 Step Study.

Philippe Lewalle, MD, Alain Delforge, PhD, Berengere Nowak, BS, Virginie Misplon, Laurence Lagneaux, PhD, Koen Theunissen, MD, PhD, Jalil Bennani, MD, Dominique Bron, MD, PhD, Philippe Martiat, MD, PhD

Blood (2004) 104 (11): 4975.

https://doi.org/10.1182/blood.V104.11.4975.4975

Published: 2004

Journal Articles

Immunological Recovery after Nonmyeloablative Transplant: A Prospective Study of 24 Patients Treated in a Single Center.

Dominique Bron, MD PhD, Van Hyunh, MD, Virginie Dewilde, MD, Jalil Bennani, MD, Philippe Lewalle, MD, Phuong Huynh, MD, Rita Leroy, Patrick Crombez, Louisette Debusscher, MD, Walter Feremans, MD, PhD, Michel Bernier, MD, Philippe Martiat, MD

Blood (2004) 104 (11): 5044.

https://doi.org/10.1182/blood.V104.11.5044.5044

Published: 2004

NARROW

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Long-Term Overall and Event-Free Survival after RIC Allogeneic Transplantation in Acute Leukemias in a Single Centre - Impact of Age and Donor Type?

Identification of the Microrna Signature of Acute Myeloid Leukemia Patient s Regulatory T Lymphocytes

Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society

Preemptive Management of Epstein-Barr Virus Reactivation after Hematopoietic Stem Cell Transplantation.

Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation (HSCT) with Mesenchymal Stem Cells (MSC) Infusion for Treatment of Metachromatic Leukodystrophy (MLD): A Case Report.

The Role of GM-CSF in Haplo-Identical Transplant Patients Who Do Not Benefit from NK Alloreactivity.

Can Addition of GM-CSF in Adult Haplo-Identical Transplant Who Cannot Benefit from NK Alloreactivity Improve the Relapse Rate of Advanced Leukemia: A 3 Step Study.

Immunological Recovery after Nonmyeloablative Transplant: A Prospective Study of 24 Patients Treated in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only